A5031246186- Prostate Cancer Treatment and Research
- Prostate Cancer Diagnosis and Treatment
- Advanced Radiotherapy Techniques
- Head and Neck Cancer Studies
- Radiomics and Machine Learning in Medical Imaging
- Radiopharmaceutical Chemistry and Applications
- Statistical Methods in Clinical Trials
- Hormonal and reproductive studies
- Medical Imaging Techniques and Applications
- Effects of Radiation Exposure
- Brain Metastases and Treatment
- Speech and Audio Processing
- Head and Neck Surgical Oncology
- Renal cell carcinoma treatment
- Advanced X-ray and CT Imaging
- Microwave Imaging and Scattering Analysis
- Salivary Gland Tumors Diagnosis and Treatment
- Cellular Mechanics and Interactions
- Biomarkers in Disease Mechanisms
- Ultrasonics and Acoustic Wave Propagation
- Cardiac tumors and thrombi
- Urologic and reproductive health conditions
- Metastasis and carcinoma case studies
- Radiation Dose and Imaging
- Cancer Risks and Factors
University of California, Los Angeles
2017-2024
Radiation Oncology Associates
2024
Chang Hua Hospital
2024
UCLA Medical Center
2021
UCLA Health
2020
University of California, San Francisco
2015
ERK signaling enables the leading edge of moving cells to generate enough force sustain forward movement.
<b>Rationale:</b> Standardized staging and quantitative reporting is necessary to demonstrate the association of <sup>18</sup>F-DCFPyL PET/CT (PSMA) imaging with clinical outcome. This work introduces an automated platform implement extend Prostate Cancer Molecular Imaging Evaluation (PROMISE) criteria - aPROMISE. The objective validate performance aPROMISE in quantifying disease burden patients prostate cancer who undergo PSMA Imaging. <b>Methods:</b> was a retrospective analysis 109...
The surrogacy of biochemical recurrence (BCR) for overall survival (OS) in localized prostate cancer remains controversial. Herein, we evaluate the BCR using different analytic methods.Individual patient data from 11 trials evaluating radiotherapy dose escalation, androgen deprivation therapy (ADT) use, and ADT prolongation were obtained. Surrogate candidacy was assessed Prentice criteria (including landmark analyses) two-stage meta-analytic approach (estimating Kendall's tau R2)....
<h3>Importance</h3> Radiotherapy combined with androgen deprivation therapy (ADT) is a standard of care for high-risk prostate cancer. However, the interplay between radiotherapy dose and required minimum duration ADT uncertain. <h3>Objective</h3> To determine specific threshold that provides distant metastasis-free survival (DMFS) benefit in patients cancer receiving external beam (EBRT) or EBRT brachytherapy boost (EBRT+BT). <h3>Design, Settings, Participants</h3> This was cohort study 3...
It has been shown that magnetic resonance imaging (MRI) guidance versus computed tomography (CT) for aggressive margin-reduction (AMR) stereotactic body radiotherapy (SBRT) in prostate cancer reduces acute toxicity, but the longer-term benefits are unknown. We performed a secondary analysis of MIRAGE, phase 3 randomized clinical trial MRI-guided SBRT cancer, to determine whether AMR with MRI significantly reduced 2-yr physician-scored or patient-reported toxic effects comparison CT guidance....
Purpose: To assess the optimal planning target volume (PTV) margins for stereotactic body radiotherapy (SBRT) of prostate cancer based on inter- and intra-fractional motion determined from daily image guidance. Methods Materials: 205 patients who were enrolled two prospective studies SBRT (8 Gy x 5 fractions) localized treated at a single institution between 2012 2017 had complete shift data available. All scheduled kilovoltage planar imaging during with rigid registration to intraprostatic...
<h3>Importance</h3> Prostate-specific membrane antigen (PSMA) positron emission tomography/computed tomography (PET/CT) can detect low-volume, nonlocalized (ie, regional or metastatic) prostate cancer that was occult on conventional imaging. However, the long-term clinical implications of PSMA PET/CT upstaging remain unclear. <h3>Objectives</h3> To evaluate prognostic significance a nomogram models an individual’s risk and to compare its performance with existing risk-stratification tools....
The optimal management strategy for high-risk prostate cancer and additional adverse clinicopathologic features remains unknown.To compare clinical outcomes among patients with after definitive treatment.This retrospective cohort study included (as defined by the National Comprehensive Cancer Network [NCCN]) at least 1 feature (defined as any primary Gleason pattern 5 on biopsy, T3b-4 disease, ≥50% cores biopsy results positive cancer, or NCCN ≥2 features) treated between 2000 2014 16...
48 Background: PSMA PETs can track treatment response in patients with prostate cancer. Recent integration of the RECIP framework PROMISE v2 allows quantitative assessment PETs. While useful for assessing differentially responding lesions, manual measurement and tracking is cumbersome PSA reliance be misleading. We evaluated an automated AI-enabled platform, aPROMISE, longitudinal lesion to evaluate based solely upon tumor volume. Methods: Patients castration sensitive or resistant disease...
Prostate-specific membrane antigen (PSMA) molecular imaging is widely used for disease assessment in prostate cancer (PC). Artificial intelligence (AI) platforms such as automated Prostate Cancer Molecular Imaging Standardized Evaluation (aPROMISE) identify and quantify locoregional distant disease, thereby expediting lesion identification standardizing reporting. Our aim was to evaluate the ability of updated aPROMISE platform assess treatment responses based on integration RECIP (Response...
To evaluate the safety of stereotactic body radiation therapy (SBRT) for prostate cancer in men with inflammatory bowel disease (IBD).We queried a consortium database patients IBD receiving SBRT between 2006 and 2012. Identified were matched without history 3:1 fashion based on dose, fractionation, use androgen deprivation therapy, age distribution. Logistic regression was used to association having experiencing acute late gastrointestinal (GI) genitourinary (GU) toxicities as scored Common...
46 Background: [F18]DCFPyL (PyL) is a PSMA targeted imaging agent that provides whole-body staging of prostate cancer. Image analysis the primary tumor using deep learning algorithms might offer additional insight into disease biology, including co-existing metastatic disease. We developed convolutional neural network (CNN) models inputs from entire on PyL images along with auto-segmented hot spots within cancer to predict synchronous metastases and compared against established built...